multivirus-specific t-cell transfer post sct vs adv, cmv and ebv infections

Conditions: AdV Infection; EBV Infection; CMV Infection; Stem Cell Transplant Complications

Summary: haematopoietic stem cell transplantation (hsct) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. adoptive transfer of virus-specific t cells is an attractive approach to restore protective t-cell immunity in patients with refractory viral infections after allogeneic hsct. the aim of this phase iii trial is to confirm efficacy of this treatment in children and adults.

for a growing number of patients suffering from various conditions as, e.g., haematological malignancies or diverse genetic disorders, haematopoietic stem cell transplantation (hsct) or bone marrow transplantation offer the only possible curative options. however, hsct is associated with three major risks: graft rejection, graft-versus-host disease (gvhd) and opportunistic, mostly viral, infections or reactivations resulting from delayed immune reconstitution. delayed immune reconstitution, however, often is the direct result of the severe pre-transplantation conditioning treatment and t-cell depletion of the transplant necessary to fight the risks of graft rejection and gvhd. therefore, the risk for life-threatening opportunistic, mostly viral, infections is increased in post-transplantation patients. the most common infections after hsct are cytomegalovirus (cmv), epstein-barr virus (ebv) and adenovirus (adv). the standard treatment approach for viral infections/reactivations is chemotherapy which shows limited efficacy and does not restore immunity. therefore, effective new treatment options are required for this condition. previous investigations have shown that sufficient t-cell immunity is essential for the control and prevention of viral reactivations and newly occurring infections after hsct. the infusion of t-cells is therefore a promising new approach to treat immune-comprised patients. however, infusion with unselected t cells is associated with an increased risk for gvhd due to the high content of alloreactive t cells. a very promising approach to minimize this problem is to remove alloreactive t cells and enrich, isolate and purify virus-specific t cells. this approach has been studied for nearly two decades and the data published up to date indicate that virus-specific t-cell responses after adoptive t-cell transfer protect against virus-related complications post hsct and restore t-cell immunity, in particular for adv-, cmv- and ebv-infections. despite these promising results, virus-specific t-cell transfer is not yet translated into daily clinical practice due to the lack of prospective clinical trials confirming the efficacy of this treatment approach. the overall goal of this phase iii, double-blind placebo-controlled study is to test efficacy of multivirus-specific t cells to bring this treatment method in clinical routine. multivirus-specific t cells generated in this study will be directed against all three most common post-hsct viral infections: adv, cmv and ebv. thus, t-cell immunity will be restored to fight and prevent new viral infections. after an initial screening visit, patients eligible to participate in the study will be treated within 28 days after screening. patients will be randomized in a 2:1 (treatment: placebo) ratio and receive a single infusion with either multivirus-specific t cells or placebo. patients will be followed up on the day of treatment, 1 day after and 1, 2, 4, 8 and 15 weeks after treatment. treatment success will be measured by assessing different parameters including symptoms, quality of life, viral load and t-cell immunity in blood samples. patients eligible to participate in this study are adult and paediatric patients who have received allogeneic stem cell transplantation and suffer from new or reactivated ebv, adv or cmv infection refractory to standard antiviral treatment for two weeks. patients from the six european countries germany, belgium, netherlands, uk, france and italy will be enrolled. in total 130 patients plus 19 screening failures are expected to participate in the study.

Eligibility criteria:
inclusion criteria: 1. adult or paediatric patients (\> 2 months of age) after allogeneic stem cell transplantation (sct) (no time restrictions apply) suffering from new or reactivated cmv or ebv or adv infection refractory to standard antiviral treatment for two weeks (defined as no decrease or insignificant decrease of less than 1log in viral load over two weeks) as confirmed by quantitative blood pcr analysis. 2. original hsct-donor available with an immune response at least to the virus causing the therapy-refractory (=underlying) infection. 3. written informed consent given (patient or legal representative) prior to any study-related procedures. exclusion criteria: 1. patient with acute gvhd \> grade ii or extensive chronic gvhd at the time of imp transfer 2. patient receiving steroids (\>1 mg/kg bw prednisone equivalent) at screening. 3. therapeutic donor lymphocyte infusion (dli) from 4 weeks prior to imp infusion until 8 weeks post imp infusion. prescheduled prophylactic dli ≤3x105 t cells/kg bw in case of t-cell depleted hsct is not considered an exclusion criterion. 4. patient with organ dysfunction or failure as determined by karnofsky (patients \>16 years) or lansky (patients ≤16 years) score ≤30% 5. concomitant enrolment in another clinical trial interfering with the endpoints of this study 6. any medical condition which could compromise participation in the study according to the investigator's assessment 7. progression of underlying disease (disease that has led to the indication of hsct, e.g. leukaemia) that will limit the life expectance below the duration of the study 8. second line or experimental antiviral treatment other than ganciclovir/valganciclovir, foscarnet, cidofovir and rituximab until 8 weeks after imp infusion or prophylactic treatment other than aciclovir or letermovir throughout the study except approved by sponsor 9. known hiv infection. in case patients do not have a negative hiv test performed within 6 months before enrolment in the study, hiv negativity has to be confirmed by a negative laboratory test. 10. female patient who is pregnant or breast-feeding. female patient of child-bearing potential (i.e. post menarche and not surgically sterilized) or male patient of reproductive potential not willing to use an effective method of birth control from screening until the last follow-up visit (fu6, visit 8). note: women of childbearing potential must have a negative serum pregnancy test at study entry ≤7 days before imp administration on day 0. acceptable birth control methods are hormonal oral contraceptive ('pill'), contraceptive injection or patch, intrauterine pessar or the combination of two barrier methods. the combination of female and male condomes is not acceptable. if the male partner is sterilized, no further contraceptive is required. women of post-menopausal status (no menses for 12 months without an alternative medical cause) are also not required to use contraceptives during the study. 11. known hypersensitivity to iron dextran 12. patients unwilling or unable to comply with the protocol or unable to give informed consent.